Form EFFECT Syros Pharmaceuticals,
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 11, 2025 |
| Accession Number: | 0001193125-25-050882 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX perpetual futures become Binance's No. 2 traded product; Binance captures over 60% market share across CEX and DEX venues
- Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged P
- FREELANDER 8 Makes First Public Appearance Ahead of Official Abu Dhabi Launch
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
